US Spending on High-Revenue Rare Disease Drugs in 2022
The American Journal of Managed Care · 2025
DOI: 10.37765/ajmc.2025.89823 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Managed Care, 2025. Verfasst von Helen Mooney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont St, Ste 3030, Boston, MA 0…. Hauptthemen laut MEDLINE: Rare Diseases, Orphan Drug Production, Prescription Drugs, Health Expenditures.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120. Email: brome@bwh.harvard.edu.
Zitieren
APA
Mooney, H., Kesselheim, A. S., & Rome, B. N. (2025). US Spending on High-Revenue Rare Disease Drugs in 2022. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2025.89823
Vancouver
Mooney H, Kesselheim AS, Rome BN. US Spending on High-Revenue Rare Disease Drugs in 2022. The American Journal of Managed Care. 2025. doi:10.37765/ajmc.2025.89823
BibTeX
@article{Mooney2025,
author = {Mooney, Helen and Kesselheim, Aaron S and Rome, Benjamin N},
title = {US Spending on High-Revenue Rare Disease Drugs in 2022},
journal = {The American Journal of Managed Care},
year = {2025},
doi = {10.37765/ajmc.2025.89823}
}
EUVIMED